Abstract Library

#4395 Mechanisms of drug resistance in neuroendocrine tumours: A basic research study

Introduction: Neuroendocrine tumours (NETs) often show resistance to chemotherapy and targeted therapies, leading to treatment failure. However, the molecular mechanisms underlying this resistance remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Chen J, Ye M, Xue B,

Keywords: Neuroendocrine tumour, drug resistance, mTOR, PI3K/AKT, tumour microenvironment, chemotherapy,

#4036 Metformin inhibits small intestinal neuroendocrine tumor proliferation in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow-growing, with most patients being diagnosed at a late stage with distant metastases. Metformin has been hypothesized as a potential anti-tumor agent by several studies in the past few years. This has been further confirmed by experimental studies in which metformin has inhibited cancer cell growth in different cancers, and we recently demonstrated that metformin treatment repressed the cell viability of SI-NET cells and inhibited the proliferation of cell spheroids.

Conference:

Presenting Author:

Authors: Axling F, Hellman P, Norlén O, Stålberg P, Barazeghi E,

Keywords: neuroendocrine neoplasm, SI-NET, in vivo model, metformin, RNA-seq, miRNA-seq, xenograft,

#4009 Hepatic metastatic model establishment of pancreatic neuroendocrine tumor by hemi-splenectomy

Introduction: The early diagnosis of pancreatic neuroendocrine tumor (pNET) patients is hard, and 60% patients are diagnosed with liver metastasis at the first visit to hospital. These patients are not suitable for surgery, which is the preferred and most effective option for pNETs. And liver metastasis promises worse outcome for patients.

Conference:

Presenting Author: Wang F

Authors: Wang F, Jing D, Zhou C, Qin Y, Chen J,

Keywords: Pancreatic neuroendocrine tumor, liver metastases, murine model, hemi-splenectomy, hepatic metastatic model,

#3724 Tackling drug activity and resistance mechanisms in neuroendocrine tumors treated with cabozantinib

Introduction: Neuroendocrine tumors (NETs) are highly vascularized malignancies and angiogenesis plays a relevant role in cell proliferation and survival. Nowadays, innovative therapies have amplified the paradigm treatment of NETs. Among the compounds with anti-vascular properties, cabozantinib (CAB) appeared promising.

Conference:

Presenting Author: Cella C

Authors: Cella C, Cazzoli R, Fazio N, de Petro G, Gaudenzi G,

Keywords: Neuroendocrine tumor, angiogenesis, zebrafish model, mouse model.,

#3722 A novel and potent Pb-212 alpha-particle therapy for NETs – Complete responses in mouse models to global clinical translation for NET patients

Introduction: A novel SSTR2 targeted peptide (VMT-alpha-NET) has been developed. Promising preclinical data have led to the initiation of multiple Phase 1 clinical trials in the United States for Pb-203 image-guided Pb-212 based alpha-particle therapy for NETs.

Conference:

Presenting Author: Schultz M

Authors: Schultz M, Johnson F, Li M, Liu D, McDonald M,

Keywords: NET, neuroendocrine tumor, alpha therapy, Pb-212, Pb-203, SPECT,